Non-intubated VATS for mediastinal neoplasmIntubated VATS for mediastinal neoplasm
Non-intubated VATS for mediastinal neoplasm: Non-intubated VATS for mediastinal neoplasm
Intubated VATS for mediastinal neoplasm: Intubated VATS for mediastinal neoplasm
Study summary
In recent year, non-intubated anesthesia had emerged as an available and promising alternative for thoracic procedure. However, its safety and feasibility in video-assisted thoracoscopic surgery (VATS) for mediastinal neoplasm remain controversial. This randomized controlled trial is designed to evaluate the impact of the non-intubated approach on surgical and perioperative outcomes in patients undergoing mediastinal neoplasm resection.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Mediastinal neoplasm was diagnosed by chest enhanced CT
2. The patients with age ≥ 18 and ≤ 80 years old
3. The patients whose tumor diameter was \<6 cm
4. ASA grade: I-III
5. The patients should understand the research and sign the informed consent
Exclusion Criteria:
1. Imaging examinations revealed that the tumor had invaded adjacent organs, with evidence of pleural or pericardial dissemination, as well as lymphatic and/or hematogenous metastases
2. Patients with a confirmed history of congestive heart failure, poorly controlled angina despite medical therapy, electrocardiogram-confirmed myocardial infarction with transmural involvement, uncontrolled hypertension, clinically significant valvular heart disease, or high-risk arrhythmias not adequately managed
3. Patients with concurrent active malignancies
Primary outcome measure(s)
Conversion rate to open surgery — postoperative in-hospital stay up to 30 days Proportion of patients requiring conversion from VATS to open surgery.
Conversion rate to intubated anesthesia — postoperative in-hospital stay up to 30 days Proportion of patients requiring conversion from non-intubated approach to intubated anesthesia
Postoperative complication rate — postoperative in-hospital stay up to 30 days Incidence and severity of treatment-related adverse events, classified by Clavien-Dindo for surgical complications and CTCAE v5.0 for systemic adverse events.
Trial sites (1)
Facility
City
Region
Status
the First Affiliated Hospital of Guangzhou Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.